Gene Therapy: Page 14
-
Courtesy of BioMarin Pharmaceutical
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
By Jacob Bell • Aug. 25, 2022 -
Getty Images
ElevateBio finds a new manufacturing home and long-term gene therapy partner in Pittsburgh
The biotech signed a 30-year deal with the University of Pittsburgh to establish a gene and cell therapy manufacturing hub that’s being built with a $100 million grant.
By Kristin Jensen • Aug. 25, 2022 -
Explore the Trendline➔
Getty Images
TrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
Getty Images
Ovid turns to gene therapy startup to restock drug pipeline
The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.
By Ben Fidler • Aug. 24, 2022 -
Permission granted by Bluebird bio
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.
By Ned Pagliarulo • Aug. 18, 2022 -
Getty Images
Bluebird gene therapy approved by FDA for rare blood disease
The regulator cleared the biotech’s medicine Zynteglo for transfusion-dependent beta thalassemia, giving patients a powerful new treatment option. But it will come at a cost of $2.8 million in the U.S.
By Ned Pagliarulo • Updated Aug. 17, 2022 -
Gene therapy safety
Novartis reports deaths of two patients treated with Zolgensma gene therapy
The deaths were due to acute liver injury, a known risk of Zolgensma and a concern for gene therapies like it.
By Ned Pagliarulo • Aug. 11, 2022 -
Permission granted by Bristol-Myers Squibb
GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum
The deal, worth as much as $2 billion, is the latest sign of industry interest in treatments that harness regulatory T cells, an approach behind several recent biotech startups.
By Ben Fidler • Aug. 10, 2022 -
Getty Images
Roche digs into off-the-shelf cell therapy with Poseida deal
The pharma has now signed two alliances with allogeneic drug developers since September, signalling its interest in CAR-T treatment alternatives.
By Ben Fidler • Aug. 3, 2022 -
Getty Images
FDA halts testing of Beam’s base editing cancer therapy
The regulator has put on hold human testing of a blood cancer treatment called BEAM-201, one of two the biotech aims to bring into clinical trials this year.
By Ben Fidler • Aug. 1, 2022 -
Courtesy of Sarepta
Sarepta to ask FDA for accelerated approval of Duchenne gene therapy
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
By Jonathan Gardner • July 29, 2022 -
Permission granted by Editas Medicine
Editas treats first patient in sickle cell trial as FDA lifts partial hold
The sickle cell therapy being studied is the second CRISPR-based medicine that Editas has advanced into clinical testing. Initial trial results could come as soon as the end of this year.
By Ned Pagliarulo • July 28, 2022 -
Courtesy of Bristol Myers Squibb
Bristol Myers CAR-T sales rise despite production problems
Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving. A manufacturing issue for Breyanzi, meanwhile, impacted sales.
By Ned Pagliarulo • July 27, 2022 -
Getty Images
State of PlayEpigenetic editing: a tunable CRISPR alternative
Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do.
By Ben Fidler • July 26, 2022 -
Getty Images
Sponsored by Bio-RadNext-level quality control in cell and gene therapy
Discover examples of how Droplet Digital™ PCR (ddPCR™) is enabling cell and gene therapies to reach further than ever before.
July 25, 2022 -
Getty Images
Freeline gives detailed look at hemophilia gene therapy results
The London-based drugmaker is currently seeking a partner to continue development of the hemophilia B treatment, which has shown promise in testing but trails a rival therapy from CSL Behring and UniQure.
By Ned Pagliarulo • July 21, 2022 -
Getty Images
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
Permission granted by Ultragenyx
Ultragenyx buys gene therapy partner after new study results
The California biotech is exercising its option to acquire GeneTx BioTherapeutics for $75 million after seeing data from the companies’ study of an Angelman syndrome treatment.
By Ned Pagliarulo • July 19, 2022 -
Getty / Edited by BioPharma Dive
Editas names new chief medical officer in latest executive change-up
Baisong Mei, a veteran of Sanofi and Biogen, comes to Editas half a year after the gene editing company fired his predecessor and one month after new CEO Gilmore O'Neill started on the job.
By Christopher Newman • Updated July 18, 2022 -
Seth Babin/BioPharma Dive
Verve starts first human test of gene editing treatment for heart disease
A patient in New Zealand became the first person to receive the biotech’s medicine, which uses base editing to turn off a specific gene in the liver and thereby lower cholesterol.
By Ned Pagliarulo • July 12, 2022 -
Getty Images
Sponsored by Ferring PharmaceuticalsC. difficile infection: Current treatment options and challenges
Clostridioides difficile infection is a highly contagious disease that affects 500,000 people in the U.S. and results in nearly 30,000 deaths per year.
By Dr. Teena Chopra • July 11, 2022 -
Permission granted by Catalent
Adverum cuts jobs, restructures to give eye gene therapy another shot
A year after reporting side effects “not seen before in ocular gene therapy” in a clinical trial, the biotech is eliminating 38% of its workforce to save cash while it runs a new study.
By Ben Fidler • July 7, 2022 -
Mario Tama via Getty Images
J&J-backed gene therapy for the eye clears early study test
Positive results for the treatment, which was developed by U.K. biotech MeiraGTx, could rebuild expectations after another gene therapy from Biogen failed in the retinal disease.
By Ned Pagliarulo • June 28, 2022 -
Getty Images
Gene therapy safety
Another Astellas gene therapy trial paused by FDA after side effect report
The regulator suspended testing of Astellas’ Pompe disease treatment after one patient experienced peripheral nerve damage. Both of the pharma’s clinical-stage gene therapies are now on hold.
By Ben Fidler • June 27, 2022 -
Kateryna Kon/Shutterstock.com
Sponsored by Ferring PharmaceuticalsC. difficile infection: A close-up on an urgent public health threat
As hospitals have dealt with surging admissions and extended stays with COVID-19, staff and patients alike have still had to contend with another potentially deadly infection from a bacterium called Clostridioides difficile.
By Dr. Dennis Deruelle • June 27, 2022 -
Getty / Edited by BioPharma Dive
BioMarin's hemophilia gene therapy recommended for approval in Europe
The decision brings what could be the first approved hemophilia gene therapy, Roctavian, closer to market, after a series of regulatory setbacks that have delayed its arrival.
By Jacob Bell • June 24, 2022
Previous
